Results 271 to 280 of about 1,615,493 (360)

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Elevated high-density lipoprotein triglycerides increase atherosclerotic risk. [PDF]

open access: yesJ Lipid Res
Liu W   +12 more
europepmc   +1 more source

Use of LC‐MS to characterize host cell protein removal during depth filtration

open access: yesBiotechnology Progress, EarlyView.
Abstract The removal of host cell proteins (HCPs) is crucial in biopharmaceutical production, as residual impurities can impact product safety and efficacy. While a number of studies have demonstrated that depth filtration can provide significant HCP removal, there is little information on its effectiveness in removing specific HCPs.
Liang‐Kai Chu   +3 more
wiley   +1 more source

Reply

open access: yes
Arthritis &Rheumatology, EarlyView.
Jie Zheng   +2 more
wiley   +1 more source

Neutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor

open access: yesCancer Communications, EarlyView.
Abstract Neutrophils are important components of the immune system and play a key role in defending against pathogenic infections and responding to inflammatory cues, including cancer. Their dysregulation indicates potential disease risk factors. However, their functional importance in disease progression has often been underestimated due to their ...
Wenpeng Cai   +6 more
wiley   +1 more source

Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma

open access: yesCancer Communications, EarlyView.
Abstract Background Intrahepatic cholangiocarcinoma (ICC) is a challenging cancer with an increasing incidence. The Phase III TOPAZ‐1/KEYNOTE‐966 study demonstrated chemo‐immunotherapy (CIT) as a significant advancement, potentially replacing traditional chemotherapy for advanced biliary tract cancer.
Jinghan Zhu   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy